Diverse Expertise Backing Extraordinary Founders

OCV Partners is a Los Angeles based venture capital firm that invests in companies with differentiated technologies in compelling target markets.

With our decades of company-building experience, our overriding objective is to use our unique expertise to identify or create an asymmetric advantage when backing winning teams.

Our core focus sectors are Technology (SaaS, FinTech, and PropTech) and Healthcare (Healthcare SaaS, Digital Health, MedTech, and Therapeutics).

Track Record of Success

We are former Founders with a track record of success

Asymmetric Advantage

We aim to create asymmetric advantages for our Founders

OCV Partners build businesses that offer asymmetric upside

We are flexible capital – we like to lead, but it is not a requirement

Focus Sector: Technology

We invest in brilliant teams building disruptive technology. As former Founders, we have grown businesses from the earliest stages to IPOs and beyond. We invest in:

  • Subscription software where we have expertise in growing and acquiring over 165 unique software companies
  • Recurring revenue business models where our past experience reveals an asymmetric advantage
  • SaaS, Fintech, and PropTech, which are areas where we have previously built companies

Focus Sector: Healthcare

We are scientists and healthcare entrepreneurs who love partnering with Founders building companies that need to exist.

We believe our investments should be challenging and changing what is possible for human health and disease.

We focus on entrepreneurs building disruptive platforms in Healthcare SaaS, Digital Health, MedTech, and Therapeutics.

We invest in companies that:

  • Enable precision or targeted approaches to improve patient lives
  • Empower better treatment decisions and optimize workflows
  • Remove barriers to care and improve equitable access
  • Expedite the discovery of new treatments

Our deep technical and operational expertise uniquely positions us to invest in and support startups at the intersection of healthcare and technology.


ByHeart To Acquire Packaging Company Cascadia Nutrition

ByHeart To Acquire Packaging Company Cascadia Nutrition

Acquisition of Packaging Facility Will Complete ByHeart's Ownership of Its End-To-End Manufacturing Process With this Acquisition, ByHeart Will Establish the first New Dedicated Infant Formula Packaging Facility in the Country to Supply the U.S. market in Over 20...

Rad AI

“The OCV team are forward-thinking investors and built their own conviction as a great multidisciplinary team that understands our vision at the intersection of healthcare and technology. They focused on building a strong relationship long before investing and have been very helpful partners after investing, on everything from introductions to market strategy.”

Doktor Gurson, CEO
1200 Pharma

“I have been working with venture investors for over 20 years and I have found OCV to be exceptionally collaborative and supportive.  The diligence process was straightforward and efficient, in no small part because the OCV team was knowledgeable in the space and thoughtful in their questions.  I believe OCV is well aligned with our company vision and engaged in making it a reality. This was demonstrated by their active and constructive involvement in helping the company to overcome a specific strategic challenge in late 2020.”

Dave Licata, CEO

“We set out to transform the infant nutrition industry at ByHeart, and to change the conversation around feeding for new parents. It has been a bold and challenging journey and OCV has been with us: as people-first investors and strong believers in our vision, they have been engaged champions of our cause, and facilitated a key partnership with a dominant market share player to help us drive forward with great momentum.”

Mia Funt (President) &
Ron Belldegrun (CEO)
Social Native

“What sets OCV apart is the amount of time they spend with us. They don’t just give advice, they roll up their sleeves and help us get actual work done. Hemi had previously led successful M&As and integrations of over 165 companies. With his help, Social Native was able to acquire Olapic a significant international competitor, in the middle of a pandemic while overcoming issues of currency, language, regulation, markets, products, and culture – all remotely.”

David Shadpour, CEO

“OCV funded us as the COVID pandemic was breaking while many other investors were retreating. They confidently formed a thesis and invested amid global uncertainty and supported us ahead of market segment growth and high-profile cyber-attacks.  OCV’s ability to have conviction to invest regardless of macro sentiment in a bold and contrarian position is what sets them apart.”

Guy Bejerano, CEO
Praxis Precision Medicines

“When building a sustainable company, it’s important to have investors early on who are deep in their diligence so they can act with conviction versus follow the status quo at the same time challenging the management team to deliver to its maximum. I found that working with OCV we got exactly that – the ideal balance of supporting the vision but also pushing us to the extra mile.”

Marcio Souza, CEO

“OCV immediately recognized what we are trying to build and why we are unique.  They made a highly relevant introduction to a key partner for us before funding.  They also invested in us as people before we had the metrics to prove our thesis.”

Matthew Gregory, CEO

“It was vital to align needed capital with vital strategic partners. The Team at OCV has delivered on both of these critical attributes. OCV has been very supportive and helpful partners, willing to engage, collaborate and lead in strategic areas such as making introductions and continued financial support when needed. Importantly, OCV has never wavered in their belief and support of our founders vision to “Transform the Patient Experience” and the “future of healthcare.”

Brian Verrier, CEO

“OCV has a deep understanding of our business and they are willing to get down in the trenches with us from hiring to pricing strategy – no detail is too small. They bring unique operating experience that you don’t typically find in venture capital.”

Mark Lenhard, CEO
Finch Therapeutics

“It has been a pleasure partnering with the team at OCV as we scaled and validated the Finch platform. Their team was thoughtfully engaged from their initial diligence through to our IPO, developing and acting on their own conviction in the opportunities to transform patient care that we are developing.”

Mark Smith, CEO
Figure 8

“OCV has delivered value beyond just capital by providing Museum of Ice Cream real estate industry expertise and access through their unique relationships. They have been an incredibly flexible and supportive partner through the different stages of our journey.”

Maryellis Bunn, CEO
Orca AI

“I was impressed with the depth of diligence OCV conducted. They spoke extensively with customers, partners, existing investors, and third-party experts which they independently sourced. They also started adding value before a deal was reached by making introductions to a large Japanese shipping company with which they had a close relationship.”

Yarden Gross, CEO

“OCV has a deep understanding of our business and they are willing to get down in the trenches with us from hiring to pricing strategy – no detail is too small. They bring unique operating experience that you don’t typically find in venture capital.”

Mark Lenhard, CEO

With our decades of company building experience, we look to create asymmetric advantages when backing winning teams.